Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esketamine combined with remimazolam for anesthesia in daytime painless abortion surgery
ChiCTR2300077901Phase 4Not yet recruiting
- Sponsor
- The First College of Clinical Medical Science, China Three Gorges University
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of esketamine and remimazolam in unintended pregnancy (3 arms), sponsored by The First College of Clinical Medical Science, China Three Gorges University. Primary endpoints: Median effective dose, Body movement response and 7 more. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
esketamineremimazolam
03
Conditions
unintended pregnancy
Beyond the preview
Go deeper on ChiCTR2300077901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077901.